Incyte beats estimates on strong cancer drug demand

What’s happening

Incyte Corporation reported stronger-than-expected quarterly results, driven by demand for cancer treatments. On April 28, 2026, the company posted total revenue of $1.27 billion, a 21% year-over-year increase, beating consensus estimates of $1.22 billion.

Adjusted earnings per share (EPS) reached $1.81, significantly surpassing the anticipated $1.35. The performance was anchored by flagship product Jakafi, which saw sales grow 7% to $758 million, and a 116% surge in the newer hematology and oncology portfolio.

What’s changing / Business impact

• Oncology demand remains strong and consistent: Net sales rose 20% to $1.10 billion, reflecting high commercial execution across all indication categories.
• Revenue supported by: established therapies like Jakafi and rapid uptake of newer assets including Niktimvo and Zynyz.
• Indicates continued investment in cancer treatment markets: R&D expenses rose 18% as the company initiated four pivotal Phase 3 trials in colorectal and pancreatic cancers.

Why this matters

This shows:

• Demand for life-saving therapies is less price-sensitive than other sectors.
• Established drugs continue generating stable revenue streams that fund transition toward a more diversified growth-oriented portfolio.
• Innovation and demand in oncology remain high-priority areas, with payers showing continued willingness to reimburse for high-efficacy outcomes.